- Patients seeking to quit smoking and using varenicline or nicotine patch had higher quit rates when using smartphone app CureApp than a sham app.
Why this matters
- Smoking cessation treatment has low success rates even with pharmacology.
- Phase 3 randomized controlled trial involving 584 adult smokers (74.5% male) intending to quit, from 31 smoking cessation clinics in Japan from October 2017 to January 2018.
- Participants received varenicline (80%) or nicotine patch (20%) during 12-week standard smoking cessation program with counseling, followed by 24 weeks use of CureApp Smoking Cessation app (CASC) or disabled sham app (control).
- CureApp included profile-customized animated video tutorials, interactive chatting with automated guidance system, digital diary, and daily exhaled CO measurements with physician access to progress.
- App was uninstalled after week 24.
- Funding: CureApp, Inc.
- Continuous abstinence rate was higher for CASC (n=285) than control (n=287) group at
- Weeks 9-12 (75.4% vs 66.2%; OR, 1.86; P=.004).
- Week 24 (63.9% vs 50.5%; OR, 1.92; P=.001).
- Week 52 (52.3% vs 41.5%; P=.01).
- 7-day point prevalence abstinence was higher for CASC vs control at weeks 4, 8, 12, 24 (72.3% vs 58.2%; P<.001 and vs p>